Mon, Jul 28, 2014, 7:59 AM EDT - U.S. Markets open in 1 hr 31 mins

Recent

% | $
Click the to save as a favorite.

Cytori Therapeutics, Inc. Message Board

rothco619 110 posts  |  Last Activity: Jul 26, 2014 12:30 PM Member since: Aug 29, 2007
  • Reply to

    10 Days Since BARDA Meeting

    by wall_street_titan Jun 20, 2014 9:30 AM
    rothco619 rothco619 Jun 25, 2014 5:39 PM Flag

    if cytx is supposed to deliver 10x's our wildest dreams then you have a long time to wait before it's too late. smart money will wait for news dumb money has been holding this pos for years , and believed the bs that was put out there by the company which was the basis of our dd.

  • rothco619 rothco619 Jun 25, 2014 12:22 PM Flag

    I thought your response was sarcastic so perhaps i misread and we are on the same page. Bottom line for all is hope we get some good news and that Mark should learn from CC and be careful what you say to shareholders

  • rothco619 rothco619 Jun 25, 2014 11:33 AM Flag

    guess you missed the point and did not bother to read the shareholder letter that was sent

  • rothco619 rothco619 Jun 25, 2014 10:32 AM Flag

    I agree but mark hendrik should not put things in writing in a letter to shareholders to once again raise expectations to only create more confusion. Some people never learn it's deja vu all over again.

  • Reply to

    Lorem Vascular Website is a joke

    by rothco619 Jun 24, 2014 5:38 PM
    rothco619 rothco619 Jun 24, 2014 8:08 PM Flag

    the website is a metaphor. it is the lack of content, or significant update from Cytori. Rickey promised better communication so did Mark. Lorem is merely a concept. A concept that Mr. Lim believes in 25 million times for 10 X;s his wildest dreams. Just looking for info to make Adam Feurstein wrong

  • Reply to

    Lorem Vascular Website is a joke

    by rothco619 Jun 24, 2014 5:38 PM
    rothco619 rothco619 Jun 24, 2014 5:59 PM Flag

    Hedge know you can't really be this obtuse. The fact that the website is a single page single statement talking about what they plan to be is disconcerting. yes or no or do you just like to be argumentative about everything , when our points are exactly the same that there is nothing happening? one would think that investing 25 million dollars in a company and there would be more to show for it then a shell company created a week before the deal which was signed in November and it is now 8 months later.

  • Reply to

    "BELIEVE" Buy now for $3.25

    by myownhedgefund Jun 24, 2014 12:35 PM
    rothco619 rothco619 Jun 24, 2014 5:54 PM Flag

    ok hedge what ever you say, read the letter it's pretty clear there is no reference to any other letter from Barda to which you refer. It's Black and white

  • Does it concern anyone that after 8 months the below message comprises the entire Lorem Vascular website and in typical Cytori facshion states that it will be a leader in cardiovascular care. It is akin to saying Cytori will be a real company one day that actually produces so revenue. Frustrating I guess that everything associated with Cytori is second rate.

    Improving Life Through Heart Health.
    Lorem Vascular will be a leader in cardiovascular care with world-class regenerative medicine therapy. Headquartered in Beijing, with offices in Hong Kong, Kuala Lumpur, Singapore, and Melbourne, Lorem Vascular is committed to advancing patient care by transforming the treatment of cardiovascular disease by providing access to innovative medical technology to facilitate regenerative medicine, hospital and physician training and continuing medical education. The Company offers a cutting-edge regenerative medicine platform for treating such things as peripheral vascular disease, acute myocardial infarction and chronic heart disease. Our flagship platform is the market-leading Celution® System developed by Cytori Therapeutics (USA).

  • Reply to

    "BELIEVE" Buy now for $3.25

    by myownhedgefund Jun 24, 2014 12:35 PM
    rothco619 rothco619 Jun 24, 2014 1:13 PM Flag

    By the time this letter is received, Cytori should have a clearer picture of the next steps under this contract.
    The word "Should" and have is an illustration of where we actually are. No statement of fact.

  • Reply to

    A "no" answer should have come quickly

    by myownhedgefund Jun 23, 2014 9:55 AM
    rothco619 rothco619 Jun 23, 2014 6:59 PM Flag

    hedge, I refer only to the timeline of the decision as expressed by hendrick, he wrote it signed it and owns it. there is nothing to be left to interpretation so a decision was expected and is perhaps taking a bit longer then expected. Normal, perhaps but again not a credible statement as of now. cleared picture can only mean an answer or they would not have a clearer picture so the intent was clear. At this point in time he mis-spoke sound familiar.

  • Reply to

    A "no" answer should have come quickly

    by myownhedgefund Jun 23, 2014 9:55 AM
    rothco619 rothco619 Jun 23, 2014 12:42 PM Flag

    others. Additionally, Cytori will fund some new indications as company sponsored trials similar to our cardiovascular trial. Expanding
    this clinical pipeline is critical to the ongoing success and value creation of the company.
    From a commercial perspective, Cytori has narrowed its efforts and related spending and is selling the current research based
    Celution® 800 primarily to customers interested in some form of clinical study using Cytori Cell Therapy. These customers are
    typically outside the U.S. and represent either academic medical departments or ‘early adopter’ physicians and clinics. These sales
    have resulted in some revenue to the company but more importantly, provide a tremendous amount of clinical feasibility
    experience, safety data, information on efficacy, and generation of intellectual property. Our near term goal is to continue these
    research sales, endeavor to move the commercial organization to a positive contribution margin and begin to leverage important
    new commercial relationships. We intend to expand this network over the near term as a cost effective way to increase the footprint
    of our technology. Longer term, the combination of the next generation system, expanded clinical data, regulatory claims and
    reimbursement will be key to driving revenue growth and overall corporate value.
    While we remain focused on clinical development and commercial success, equally important to many of our shareholders with
    whom I have spoken, is to ensure that Cytori grows in financial strength and is able to take full advantage of its technology. I whole- heartedly concur. As CEO, I will personally do all I can to ensure we wisely invest our resources and focus the use of those resources
    on only those projects most likely to bring the highest return on investment.
    I look forward to updating you on our progress in these areas. Thank you for your continued interest and investment in Cytori.
    Sincerely,
    Marc H. Hedrick, MD
    President and Chief Executive Officer
    June 16, 2014
    Cautionary Statement Regarding Forward-Looking Statements
    This Shareholder update includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts,
    including statements regarding: the Cytori Cell Therapy mechanisms of action, potential safety and efficacy signals from the ATHENA trials, our ability to obtain FDA
    approval of Cytori Cell Therapy for burn therapy, our ability to develop Cytori Cell Therapy as a pre-deployed medical counter measure, our ability to improve the
    automation, cost effectiveness, processing time and performance of our next generation Celution System, and expand our clinical pipeline and target indications, our
    ability to achieve positive contribution margin from our commercial operations, and cost effectively leverage new partners and customers to drive sales and profit
    growth, and our ability to obtain expanded contract options with BARDA, are forward looking statements. Such statements are subject to risks and uncertainties that
    could cause our actual results and financial position to differ materially. Some of these risks include our need to raise more cash in the future, our level of indebtedness
    and covenant restrictions under such indebtedness, the level of future interest in our products, the performance of our distribution networks, clinical, pre-clinical and
    regulatory uncertainties, such as those associated with the ATHENA clinical trial and the BARDA contract options, including risks in the collection and results of clinical
    data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports.
    There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and
    prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the
    date they are made unless we have an obligation under U.S. Federal securities laws to do so.
    others. Additionally, Cytori will fund some new indications as company sponsored trials similar to our cardiovascular trial. Expanding
    this clinical pipeline is critical to the ongoing success and value creation of the company.
    From a commercial perspective, Cytori has narrowed its efforts and related spending and is selling the current research based
    Celution® 800 primarily to customers interested in some form of clinical study using Cytori Cell Therapy. These customers are
    typically outside the U.S. and represent either academic medical departments or ‘early adopter’ physicians and clinics. These sales
    have resulted in some revenue to the company but more importantly, provide a tremendous amount of clinical feasibility
    experience, safety data, information on efficacy, and generation of intellectual property. Our near term goal is to continue these
    research sales, endeavor to move the commercial organization to a positive contribution margin and begin to leverage important
    new commercial relationships. We intend to expand this network over the near term as a cost effective way to increase the footprint
    of our technology. Longer term, the combination of the next generation system, expanded clinical data, regulatory claims and
    reimbursement will be key to driving revenue growth and overall corporate value.
    While we remain focused on clinical development and commercial success, equally important to many of our shareholders with
    whom I have spoken, is to ensure that Cytori grows in financial strength and is able to take full advantage of its technology. I whole- heartedly concur. As CEO, I will personally do all I can to ensure we wisely invest our resources and focus the use of those resources
    on only those projects most likely to bring the highest return on investment.
    I look forward to updating you on our progress in these areas. Thank you for your continued interest and investment in Cytori.
    Sincerely,
    Marc H. Hedrick, MD
    President and Chief Executive Officer

  • Reply to

    A "no" answer should have come quickly

    by myownhedgefund Jun 23, 2014 9:55 AM
    rothco619 rothco619 Jun 23, 2014 12:36 PM Flag

    TO MY FELLOW SHAREHOLDERS:
    On behalf of our organization, I wish to first thank you for your continued support for
    Cytori and its mission and also provide an update as of mid 2014.
    In the U.S., patients with ischemic heart disease refractory to current treatments are
    being enrolled in our cardiovascular trials. Scientifically, Cytori Cell Therapy appears to
    improve the functioning of the heart through a number of mechanisms, including
    improving blood flow via release of specific growth factors as well as direct differentiation
    and regulation of cells into blood vessels. Preliminary evidence of clinical efficacy and
    support of the mechanism of action was shown in the European PRECISE trial. This trial
    showed a favorable benefit to risk profile and was recently published in the American
    Heart Journal. Continued safety and efficacy signals in our ongoing ATHENA trials may lay
    the foundation for a U.S. ‘approval’ trial in the future.
    Also, Cytori is the recipient of a contract from the United States government, specifically
    the Biomedical Advanced Research and Development Authority (BARDA), to develop a
    medical countermeasure with the goal of adapting Cytori Cell Therapy to aid in the event
    of a mass casualty situation involving thermal burns with concomitant radiation exposure. We have successfully achieved the
    objectives of the base period of this contract and have met with BARDA leadership to discuss execution of option 1 under the
    contract. During the base period, preclinical studies have shown that Adipose Derived Regenerative Cells (ADRCs™) enhance healing
    of full thickness burn wounds in both irradiated and non-irradiated subjects. The mechanism of action, as in cardiovascular disease,
    seems to be the regeneration of tissue via paracrine release of growth factors.
    Going forward, we hope to expand this current contract in two directions. First, if awarded option 1, Cytori will seek FDA-approval
    for use of Cytori Cell Therapy in the clinical treatment of burn injuries. Secondly, if contract option 2 is subsequently awarded, Cytori
    would develop Cytori Cell Therapy for use as a pre-deployed medical countermeasure for thermal burns complicated by radiation
    exposure. By the time this letter is received, Cytori should have a clearer picture of the next steps under this contract.
    In addition, over the past two years, Cytori has expanded its team and capabilities to handle increasingly complex government
    contracting requirements and is seeking new ways to leverage this expertise to other contracting opportunities and funding sources
    that would both expand our clinical opportunities and reduce our capital requirements.
    I would also like to highlight an important aspect of our BARDA contract that is often overlooked. That is the potential for significant
    development support from the United States government for the next generation Celution® technology. This proprietary technology
    is the foundation of every Cytori Cell Therapy treatment and is at the core of the business model. Though critical for successful
    implementation of a BARDA directed medical countermeasure, the next generation system will be a significant improvement on
    current technology based on its automation, cost effectiveness, processing time and performance enhancements. This combination
    of features will create a unique autologous cell therapy ecosystem at the bedside, capable of integrating into many clinical settings
    and targeting a wide range of medical conditions. We will update you on the timeline as we get closer to launching the next
    generation Celution® System.
    Furthermore, the next generation system, with its inherent performance and cost benefits, allows Cytori to expand its clinical
    pipeline into new areas where cost, processing time or performance is critical to the value proposition. Orthopedic and sports
    medicine related conditions, wound healing, and aesthetic indications are just a few areas that could be better addressed by this
    next generation system. Building on the forthcoming next generation platform and incoming data from investigator driven studies, Cytori intends in the near
    term to expand its clinical pipeline and target indications into new areas. Some of these will be facilitated by external support, as is
    the case for burn treatment funded in part by the U.S. government, urinary incontinence funded by the Japanese government, and

  • Reply to

    A "no" answer should have come quickly

    by myownhedgefund Jun 23, 2014 9:55 AM
    rothco619 rothco619 Jun 23, 2014 12:01 PM Flag

    As I posted previously in the letter to shareholders for annual meeting which i received and you all should have as well Mark Hendrik stated that by the time we received said letter, that Cytori and shareholders should have information on the status. Point being we have received the letter yet there is no update. true to form mis information. I had also said that perhaps we might receive info today if we were lucky. In the letter management sure has put quite a bit on BARDA. so they must be counting on it. based on activity on PPS don't know just how meaningful an impact good news on BARDA will actually have. We all agree on what will happen with a rejection.

  • Well Mr Hendrick, I have received the letter so why do I not have a cleared picture of the next steps under the contract id you do. When you make a statement then follow up on it. Maybe Monday.

    Going forward, we hope to expand this current contract in two directions. First, if awarded option 1, Cytori will seek FDA-approval
    for use of Cytori Cell Therapy in the clinical treatment of burn injuries. Secondly, if contract option 2 is subsequently awarded, Cytori
    would develop Cytori Cell Therapy for use as a pre-deployed medical countermeasure for thermal burns complicated by radiation
    exposure. By the time this letter is received, Cytori should have a clearer picture of the next steps under this contract.

  • Reply to

    10 Days Since BARDA Meeting

    by wall_street_titan Jun 20, 2014 9:30 AM
    rothco619 rothco619 Jun 20, 2014 11:23 AM Flag

    same is true for rejection not to.very nerve wracking and price does not reflect optimism,although I can't imagine why it would based on history. It is a wait and see, why take the risk on a guess, better to buy or sell with firm answer at this point

  • Reply to

    Option Week

    by jamesdean274 Jun 18, 2014 12:02 PM
    rothco619 rothco619 Jun 19, 2014 10:29 AM Flag

    It will all be history soon and that is a BIG IF

  • rothco619 rothco619 Jun 18, 2014 5:36 PM Flag

    definitely will not suffer with this ineptitude for another 4 years

  • rothco619 rothco619 Jun 18, 2014 2:11 PM Flag

    one would think that CC on his junket to europe may have been able to land a partnership deal for sports medicine aplications of stem cells. even a frog bumps its a $ $ every once in awhile so perhaps a going away present in the offing. not going to hold my breath though.

  • rothco619 rothco619 Jun 18, 2014 12:10 PM Flag

    Don't you just love the thumbs down from the idiots on this message board any time they hear a comment that is true. Always the rule rather then the exception, wonder why we bother.

  • rothco619 rothco619 Jun 18, 2014 9:51 AM Flag

    After so many delays it will be interesting to see if they actually open on revised date and treat any patients in august. i say based on history, the answer is no. That is not to diminish the task they are under taking just that we have had nothing but delays.

CYTX
2.12-0.04(-1.85%)Jul 25 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
El Pollo Loco Holdings, Inc.
NasdaqGSFri, Jul 25, 2014 4:00 PM EDT
Dollar Tree, Inc.
NasdaqGSFri, Jul 25, 2014 4:00 PM EDT